Tyler Van Buren

Tyler Van Buren is a Managing Director and senior equity research analyst on the biotechnology team at TD Cowen.

Mr. Van Buren has a decade and a half of equity research experience and is responsible for providing analysis on large-, mid-, and small-cap biotechnology stocks. His views on biotechnology topics are often quoted by national news services such as Bloomberg, Endpoints News, Reuters, STAT, and the Wall Street Journal, and he has been featured as a guest on CNBC and Fox News.

Prior to rejoining TD Cowen, Mr. Van Buren was a Managing Director and senior biotechnology equity research analyst at Piper Sandler (previously Piper Jaffray) for over three years. Prior to Piper Sandler, Mr. Van Buren spent five years on the biopharma research team at TD Cowen. Previously, Van Buren was a founding member and Managing Director at LifeSci Advisors where he helped build the firm’s biotechnology research practice. Earlier in his career, he worked at Amylin Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham Medical Research Institute, and the U.S. Department of Agriculture.

Mr. Van Buren earned a master’s degree in biology and a bachelor’s degree in biochemistry and cellular biology from the University of California, San Diego.

HCBiopharma